Gp100 (619-627) is amino acids 619 to 627 fragment of human melanoma antigen glycoprotein 100 (gp100). Gp100 has been a widely studied target for melanoma immunotherapy.
Gp100 619-627 is a synthetic peptide fragment corresponding to amino acids 619 to 627 of the human gp100 glycoprotein, a melanocyte differentiation antigen. As a well-characterized epitope, it plays a significant role in immunological studies, particularly those focused on melanoma research and antigen presentation mechanisms. The peptide's defined sequence and immunogenic properties make it a valuable tool in the investigation of T cell recognition, peptide-MHC binding, and the broader understanding of antigen processing pathways in cellular immunology. Its use is well established in experimental systems where precise control over antigenic stimulation is required, enabling researchers to dissect immune responses at the molecular level.
Epitope mapping: The 619-627 fragment of gp100 is frequently employed in epitope mapping studies to identify and characterize T cell responses specific to melanoma-associated antigens. By presenting this peptide to antigen-presenting cells in vitro, researchers can investigate the binding affinity and specificity of T cell receptors, facilitating the delineation of immunodominant regions within the gp100 protein. This application is instrumental for understanding the fine specificity of immune recognition and for identifying candidate epitopes for further immunological research.
Antigen presentation research: In studies focused on the mechanisms of antigen processing and presentation, the gp100-derived peptide serves as a model substrate for loading onto major histocompatibility complex (MHC) class I molecules. Using this well-defined peptide, investigators can examine the efficiency and dynamics of peptide-MHC complex formation, stability, and subsequent T cell activation. Such research provides critical insights into the molecular interactions governing immune surveillance and the cellular pathways that regulate antigen display.
T cell activation assays: The gp100 619-627 peptide is widely utilized in functional assays designed to assess CD8+ cytotoxic T lymphocyte (CTL) responses. By pulsing target cells with the peptide, researchers can quantitatively evaluate T cell activation, cytokine secretion, and cytolytic activity in vitro. This approach is essential for exploring T cell functionality, validating immune response assays, and optimizing protocols for adoptive cell transfer experiments or immune monitoring in preclinical studies.
Vaccine development research: As a prototypical tumor-associated antigenic peptide, the gp100 619-627 sequence is incorporated into experimental vaccine formulations and immunogenicity studies. Its use allows scientists to probe the parameters influencing peptide-based vaccine efficacy, such as adjuvant selection, delivery strategies, and immune potentiation. These investigations support the rational design of next-generation immunotherapeutic approaches targeting cancer antigens at the peptide level.
Peptide-MHC binding studies: The defined sequence of the gp100 619-627 epitope makes it an ideal candidate for quantitative and structural analyses of peptide-MHC interactions. Researchers employ this peptide in binding affinity assays, crystallography, and computational modeling to elucidate the structural determinants of antigen presentation. Such studies contribute to the broader understanding of immune recognition and inform the design of synthetic peptides with optimized binding characteristics for research and development purposes.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More